Synektik plans to finish phase I of its cardio-marker's clinical research in the next few weeks. The innovative medical solutions company received PLN 21.3 million in subsidies, PLN 15.7 million of which does not require own contribution. The board is currently working on a schedule for research which will be carried out in Poland. Phase III will be conducted in the US. The potential for heart muscle perfusion tests in the US is huge, with 8 million test carried out annually. In Europe, about 3 million tests are done each year. During phase II or III, Synektik would like to sign an agreement with a partner who could then start manufacturing the device in the US.